# 177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors

> **NCT06632873** · EARLY_PHASE1 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 10 (estimated)

## Conditions studied

- SSTR2 and Integrin αVβ3 Positive Tumors

## Interventions

- **DRUG:** 177Lu-TATE-RGD

## Key facts

- **NCT ID:** NCT06632873
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-02-20
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06632873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06632873, "177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06632873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*